- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00588328
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
December 23, 2015 updated by: Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out whether a new device can help obtain more accurate CT and PET scans of the lungs and chest tumors and the liver and liver tumors to help in delivering radiation therapy.
When we breathe, the amount of air in the lung changes.
Lung tumors may also move during breathing.
Liver tumors may also move with breathing; as the lungs inflate, the liver can be pushed down.
A CT scan (a special type of X-ray) is routinely obtained as part of planning for lung or liver radiation therapy.
Since patients breathe during this CT scan and their lung or liver tumors move, these CT scans can sometimes be inaccurate.
We are now testing a device to only obtain the CT and an additional PET scan while patients are breathing in or out.
This will hopefully allow us to deliver radiation with more accuracy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objectives are to measure the amount of tumor motion with respiration, measure changes in tumor definition with breathing synchronized PET compared to standard free breathing PET, and to determine the fraction of patients whose radiation treatment plans would be modified based on this information.
Eligible patients are those receiving radiation treatment for thoracic or liver tumors.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Ability to sign informed consent form indicating investigative nature of this study, in keeping with the policies of the hospital.
- Patients must have thoracic disease visible on a Chest CT scan, or liver disease visible on a abdominal CT scan.
Exclusion Criteria:
- Pregnant women are ineligible. A pregnancy test will be performed on each fertile premenopausal female prior to entry into the study.
- Patients with thoracic or liver disease that is not visible on CT scan
- Patients who are unable to follow directions either due to language difficulties or hearing impairment.
- Patients who are too ill to hold their breath.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
PET/CT scans
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the amount of tumor motion in breathing synchronized CT scans and determine the fraction of patients whose radiation treatment planning margins would be modified based on this information.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure changes in tumor definition with breathing synchronized PET compared to standard free breathing PET, and determine the fraction of patients whose radiation treatment plans would be modified based on this information.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Kenneth Rosenzweig, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2000
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
May 1, 2010
Study Registration Dates
First Submitted
December 20, 2007
First Submitted That Met QC Criteria
December 21, 2007
First Posted (Estimate)
January 8, 2008
Study Record Updates
Last Update Posted (Estimate)
December 24, 2015
Last Update Submitted That Met QC Criteria
December 23, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00-008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
SCRI Development Innovations, LLCBiogenCompleted
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
Clinical Trials on PET/CT scan
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
HALO DiagnosticsCompletedProstate CancerUnited States
-
Radboud University Medical CenterUnknownCarcinoma, Non Small Cell LungNetherlands
-
University of RochesterTerminatedChronic Graft Versus Host DiseaseUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonRecruiting
-
Colchester General HospitalAnglia Ruskin UniversityUnknownRectal NeoplasmsUnited Kingdom
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedLymphoma | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung CancerCanada
-
Radboud University Medical CenterABX advanced biochemical compounds GmbH; Radboud Translational MedicineRecruitingProstate Cancer RecurrentNetherlands
-
GE HealthcareLaboratory Corporation of AmericaNot yet recruiting
-
Columbia UniversityActive, not recruitingProstatic NeoplasmsUnited States